# Exact Sciences

Type: Company (EXAS)

Source: GetYourBrief — https://getyourbrief.com/entity/exact-sciences
Canonical HTML page: https://getyourbrief.com/entity/exact-sciences

## Timeline

- **2026-07-07**: Global Milestone Announcement — Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company.
- **2026-07**: FDA Breakthrough Device Designation — The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening.
- **2026-06**: ASCO Breakthrough 2026 — Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore.

## Recent coverage (7 stories, network-wide)

### Abbott's 42% Diagnostics Surge vs Thermo Fisher's Recovery: Which Wins?
2026-08-24 02:36:34 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.
Full story: https://gethealthbrief.com/story/abbott-thermo-fisher-health-diagnostics-vs-recovery

### FDA Breakthrough Designation for SPOT-MAS 10 Validates Asia-Led Liquid Biopsy Innovation
2026-07-22 05:21:09 · Sector: bio · Sentiment: Strongly positive · Impact: 6/10 · Sources: 3

Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia.
Full story: https://getbiobrief.com/story/gene-solutions-spot-mas-fda-breakthrough

### 84,145-Patient Study Propels Gene Solutions' SPOT-MAS 10 to Asian Cancer Screening Forefront
2026-07-22 05:19:29 · Sector: health · Sentiment: Strongly positive · Impact: 6/10 · Sources: 3

A massive real-world study and FDA Breakthrough Device Designation position SPOT-MAS 10 as a potential paradigm shift in multi-cancer screening across Asian healthcare systems, offering a non-invasive, population-validated tool to combat rising cancer burdens.
Full story: https://gethealthbrief.com/story/gene-solutions-spot-mas-asian-cancer-screening

### Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth
2026-07-17 03:46:04 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.
Full story: https://gethealthbrief.com/story/abbott-2026-profit-forecast-device-growth

### Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60
2026-07-17 03:45:55 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
Full story: https://getbiobrief.com/story/abbott-cancer-diagnostics-2026-eps-forecast

### Mid-Cap Healthcare Stocks Hit Oversold Territory Amid Middle East Volatility
2026-03-17 14:53:42 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 3

A sharp sell-off in mid-cap healthcare stocks has pushed several key players into technically oversold territory as geopolitical tensions in the Middle East trigger a broader market retreat. Investors are rotating out of riskier mid-sized equities, creating potential entry points for value-oriented healthcare analysts.
Full story: https://gethealthbrief.com/story/mid-cap-healthcare-oversold-middle-east-volatility

### Mid-Cap Healthcare Stocks Surge in Quant Rankings Following Earnings Season
2026-03-14 15:35:12 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mid-cap healthcare stocks are seeing a significant re-rating as quantitative models prioritize profitable growth and upward analyst revisions. Following a strong earnings season, the diagnostic and med-tech sub-sectors have emerged as the primary drivers of sector outperformance.
Full story: https://gethealthbrief.com/story/mid-cap-healthcare-quant-rankings-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.